Log in

Relevant bibliographies by topics / Psychopharmacology; Neuroscience / Journal articles

To see the other types of publications on this topic, follow the link: Psychopharmacology; Neuroscience.

Journal articles on the topic 'Psychopharmacology; Neuroscience'

Author: Grafiati

Published: 4 June 2021

Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Psychopharmacology; Neuroscience.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Birnbaum, Robert J. "Neuroscience and Psychopharmacology into the Next Millennium." CNS Spectrums 4, no. 7 (July 1999): 36–52. http://dx.doi.org/10.1017/s1092852900012001.

Full text

Abstract:

AbstractThe end of the millennium provides an opportunity to review some of the common practices that were present in psychopharmacology during the 20th century. The author focuses on two approaches that have dominated research and guided the clinical application of psychopharmacologic therapeutics: the unitary clinically-based and single-lesion perspectives. The author expands upon these older formulations of neuropsychiatric disease pathogenesis and describes how the approach to psychopharmacologic research and therapeutics has changed in light of advances in the basic neurosciences. Relevant recent advances in the basic neurosciences that shed light on the pathophysiology of neuropsychiatric disease states and that guide psychopharmacologic practices are described. The use of atypical antipsychotic agents to treat schizophrenia is given as one example of the clinical applications of the approach to psychopharmacology in the next century.

APA, Harvard, Vancouver, ISO, and other styles

2

Uchida, Hiroyuki, Shigeto Yamawaki, Won-Myong Bahk, and Duk-In Jon. "Neuroscience-based Nomenclature (NbN) for Clinical Psychopharmacology and Neuroscience." Clinical Psychopharmacology and Neuroscience 14, no. 2 (May 31, 2016): 115–16. http://dx.doi.org/10.9758/cpn.2016.14.2.115.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Minchin, M. C. W. "Psychopharmacology." Neuropharmacology 25, no. 1 (January 1986): 109. http://dx.doi.org/10.1016/0028-3908(86)90066-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Nutt, David J., and Pierre Blier. "Neuroscience-based Nomenclature (NbN) for Journal of Psychopharmacology." Journal of Psychopharmacology 30, no. 5 (April 19, 2016): 413–15. http://dx.doi.org/10.1177/0269881116642903.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Gorman, Adrienne M., and Karen M. Doyle. "Considerations and recent advances in neuroscience." Biochemical Society Transactions 37, no. 1 (January 20, 2009): 299–302. http://dx.doi.org/10.1042/bst0370299.

Full text

Abstract:

Neuroscience is a rapidly developing area of science which has benefitted from the blurring of interdisciplinary boundaries. This was apparent in the range of papers presented at this year's Neuroscience Ireland Conference, held in Galway during August 2008. The event was attended by academics, postdoctoral and postgraduate researchers, scientists from industry and clinicians. The themes of this year's conference, neurodegeneration, neuroregeneration, pain, glial cell biology and psychopharmacology, were chosen for their reflection of areas of strength in neuroscience within Ireland. In addition to basic science, translational research also featured strongly.

APA, Harvard, Vancouver, ISO, and other styles

6

Vrecko, Scott. "Neuroscience, power and culture: an introduction." History of the Human Sciences 23, no. 1 (February 2010): 1–10. http://dx.doi.org/10.1177/0952695109354395.

Full text

Abstract:

In line with their vast expansion over the last few decades, the brain sciences — including neurobiology, psychopharmacology, biological psychiatry, and brain imaging — are becoming increasingly prominent in a variety of cultural formations, from self-help guides and the arts to advertising and public health programmes. This article, which introduces the special issue of History of the Human Science on ‘Neuroscience, Power and Culture’, considers the ways that social and historical research can, through empirical investigations grounded in the observation of what is actually happening and has already happened in the sciences of mind and brain, complement speculative discussions of the possible social implications of neuroscience that now appear regularly in the media and in philosophical bioethics. It suggests that the neurosciences are best understood in terms of their lineage within the ‘psy’-disciplines, and that, accordingly, our analyses of them will be strengthened by drawing on existing literatures on the history and politics of psychology — particularly those that analyze formations of knowledge, power and subjectivity associated with the discipline and its practical applications. Additionally, it argues against taking today’s neuroscientific facts and brain-targetting technologies as starting points for analysis, and for greater recognition of the ways that these are shaped by historical, cultural and political-economic forces.

APA, Harvard, Vancouver, ISO, and other styles

7

Marsden, Charles A., and André Rex. "Transgenics and Psychopharmacology Introduction." Reviews in the Neurosciences 11, no. 1 (January 2000): 1–2. http://dx.doi.org/10.1515/revneuro.2000.11.1.1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Lehmann, Heinz E., and Thomas A. Ban. "The History of the Psychopharmacology of Schizophrenia." Canadian Journal of Psychiatry 42, no. 2 (March 1997): 152–62. http://dx.doi.org/10.1177/070674379704200205.

Full text

Abstract:

Objective: To review the historical development of the psychopharmacological treatment of schizophrenia. Method: A chronological literature review of the clinical practices and theoretical models that have controlled drug treatment of schizophrenia at different times. Results: Effective treatment of schizophrenia was achieved only after the introduction of antipsychotic drugs, in the 1950s, and is still progressing. Conclusion: Close collaboration between basic neuroscience and careful and informed clinical practice are likely to lead to continued progress.

APA, Harvard, Vancouver, ISO, and other styles

9

Leccese, Arthur. "Pharmacophobic psychopharmacology." Pharmacology Biochemistry and Behavior 46, no. 2 (October 1993): 497. http://dx.doi.org/10.1016/0091-3057(93)90396-b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Hynie, S. "Psychopharmacology: An Introduction." Neuropharmacology 25, no. 12 (December 1986): 1408. http://dx.doi.org/10.1016/0028-3908(86)90124-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Tang, Siu W., Wayne H. Tang, and Brian E. Leonard. "Herbal medicine for psychiatric disorders: Psychopharmacology and neuroscience-based nomenclature." World Journal of Biological Psychiatry 20, no. 8 (July 11, 2017): 586–604. http://dx.doi.org/10.1080/15622975.2017.1346279.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Veenstra-VanderWeele, Jeremy. "1.1 EMERGING NEUROSCIENCE-BASED PSYCHOPHARMACOLOGY IN CHILD AND ADOLESCENT PSYCHIATRY." Journal of the American Academy of Child & Adolescent Psychiatry 58, no. 10 (October 2019): S129. http://dx.doi.org/10.1016/j.jaac.2019.07.615.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Paz, Rodrigo D., Sonia Tardito, Marco Atzori, and Kuei Y. Tseng. "Glutamatergic dysfunction in schizophrenia: From basic neuroscience to clinical psychopharmacology." European Neuropsychopharmacology 18, no. 11 (November 2008): 773–86. http://dx.doi.org/10.1016/j.euroneuro.2008.06.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Pellow, Sharon. "Theory in Psychopharmacology: Vol. 2." Trends in Neurosciences 8 (January 1985): 223–24. http://dx.doi.org/10.1016/0166-2236(85)90084-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Hynie, S. "Assessment in Geriatric Psychopharmacology." Neuropharmacology 25, no. 12 (December 1986): 1407. http://dx.doi.org/10.1016/0028-3908(86)90122-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Pae, Chi-Un. "Taking a Responsibility for Future Progression of Clinical Psychopharmacology and Neuroscience." Clinical Psychopharmacology and Neuroscience 18, no. 2 (May 31, 2020): 172–73. http://dx.doi.org/10.9758/cpn.2020.18.2.172.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Ranen, Neal G. "Human psychopharmacology measures and methods." Electroencephalography and Clinical Neurophysiology 98, no. 3 (March 1996): 227. http://dx.doi.org/10.1016/s0013-4694(96)90292-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

No authorship indicated. "Experimental and Clinical Psychopharmacology Call for Papers: Special Issue on Recent Advances in Psychopharmacology and Mental Health." Behavioral Neuroscience 120, no. 5 (2006): 1032. http://dx.doi.org/10.1037/0735-7044.120.5.1032.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Sultan, Ryan S., Christoph U. Correll, Joseph Zohar, Gil Zalsman, and Jeremy Veenstra-VanderWeele. "What’s in a Name? Moving to Neuroscience-Based Nomenclature in Pediatric Psychopharmacology." Journal of the American Academy of Child & Adolescent Psychiatry 57, no. 10 (October 2018): 719–21. http://dx.doi.org/10.1016/j.jaac.2018.05.024.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Cavanna, Andrea E. "On the Philosophy of Psychopharmacology." Cognitive Neuropsychiatry 20, no. 6 (September 14, 2015): 551–54. http://dx.doi.org/10.1080/13546805.2015.1085207.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Hamrin, Vanya, and Joanne DeSanto Iennaco. "Psychopharmacology of pediatric bipolar disorder." Expert Review of Neurotherapeutics 10, no. 7 (July 2010): 1053–88. http://dx.doi.org/10.1586/ern.10.86.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Siegel, Shepard, and Michael T. Scoles. "Psychoneuroimmunology, psychopharmacology, and synthetic physiology." Behavioral and Brain Sciences 8, no. 3 (September 1985): 409–10. http://dx.doi.org/10.1017/s0140525x00000960.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Bracken, Pat, Philip Thomas, Sami Timimi, Eia Asen, Graham Behr, Carl Beuster, Seth Bhunnoo, et al. "Psychiatry beyond the current paradigm." British Journal of Psychiatry 201, no. 6 (December 2012): 430–34. http://dx.doi.org/10.1192/bjp.bp.112.109447.

Full text

Abstract:

SummaryA series of editorials in this Journal have argued that psychiatry is in the midst of a crisis. The various solutions proposed would all involve a strengthening of psychiatry's identity as essentially ‘applied neuroscience’. Although not discounting the importance of the brain sciences and psychopharmacology, we argue that psychiatry needs to move beyond the dominance of the current, technological paradigm. This would be more in keeping with the evidence about how positive outcomes are achieved and could also serve to foster more meaningful collaboration with the growing service user movement.

APA, Harvard, Vancouver, ISO, and other styles

24

Brühl, A. B., and B. J. Sahakian. "Neuroscience-based Nomenclature: improving clinical and scientific terminology in research and clinical psychopharmacology." Psychological Medicine 47, no. 8 (January 18, 2017): 1339–41. http://dx.doi.org/10.1017/s0033291716003603.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Spealman, Roger D. "Cocaine receptors: Significance for psychopharmacology." Pharmacology Biochemistry and Behavior 36, no. 2 (June 1990): 423. http://dx.doi.org/10.1016/0091-3057(90)90429-l.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Goldman, Mark. "Psychopharmacology: Clinical research and therapy." Pharmacology Biochemistry and Behavior 36, no. 2 (June 1990): 430. http://dx.doi.org/10.1016/0091-3057(90)90463-r.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Ray, Oakley S. "A model curriculum in psychopharmacology." Pharmacology Biochemistry and Behavior 36, no. 2 (June 1990): 430. http://dx.doi.org/10.1016/0091-3057(90)90465-t.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

BENZI, Ilaria M. A., Rossella DI PIERRO, Pietro DE CARLI, Ioana Alina CRISTEA, and Pietro CIPRESSO. "All the Faces of Research on Borderline Personality Pathology: Drawing Future Trajectories through a Network and Cluster Analysis of the Literature." Journal of Evidence-Based Psychotherapies 20, no. 2 (September 1, 2020): 3–30. http://dx.doi.org/10.24193/jebp.2020.2.9.

Full text

Abstract:

"Borderline Personality Disorder is a severe condition that affects self and interpersonal dimensions and emotional and behavioral regulation. Since the last decades of the 20th century, an impressive amount of research and clinical contributions on BPD came from specific fields such as psychiatry, clinical psychology, psychopharmacology, and, more recently, cognitive neuroscience. All contributions tackled the challenges of finding reliable diagnostic categories, highlighting detailed developmental trajectories, and fostering effective treatment protocols. However, as results come from different areas, it is often challenging to depict a coherent and yet multifaceted framework on this topic. In this study, we conducted a scientometric analysis of the available literature on BPD to provide a systematic and comprehensive overview of research on BPD and emphasize historical changes, intertwining between fields and new areas of investigation. Results clearly show the evolution of research on BPD starting from the initial development of the construct, passing through the studies on treatment efficacy, the results of longitudinal studies, the advances in cognitive neurosciences, and the recent dimensional conceptualization in DSM-5. Moreover, it emphasizes promising areas of investigation, such as the relations of BPD with NSSI, ADHD, and vulnerable features of narcissism."

APA, Harvard, Vancouver, ISO, and other styles

29

Klein, Donald F. "Counterevidence from psychopharmacology, psychopathology, and psychobiology." Behavioral and Brain Sciences 18, no. 2 (June 1995): 302–3. http://dx.doi.org/10.1017/s0140525x00038553.

Full text

Abstract:

AbstractDavey's discussion of phobias is criticized because of the lack of distinctions between the various classes of phobias. Psychopharmacological evidence indicates differing pathophysiologies. Clinical psychopharmacological distinctions are not congruent with either a strict phylogenetic preparedness model or with cognitive biases. Davey's critique of the laboratory bred animal studies seems far fetched. His hypothesis concerning the importance of historical significance is clearly ad hoc rather than based on comparative data.

APA, Harvard, Vancouver, ISO, and other styles

30

Pawlak, Cornelius R., Britta D. Karrenbauer, Peggy Schneider, and Ying-Jui Ho. "The Elevated Plus-Maze Test: Differential Psychopharmacology of Anxiety-Related Behavior." Emotion Review 4, no. 1 (January 2012): 98–115. http://dx.doi.org/10.1177/1754073911421374.

Full text

Abstract:

The role of individual factors in behavioral neuroscience is an important, but still neglected, area of research. For example, the Elevated Plus-Maze Test has been one of the most used paradigms to gauge unconditioned aversively motivated behavior in rodents. However, despite a great number of experiments with this test there have been only few efforts to assess systematic individual variations in the elevated plus-maze and related neurobiological functions. The present review aims to give, first, a general overview and introduction about the test, and second, an animal model of anxiety based on natural variance of plus-maze behavior within a given unselected population of rats. Finally, critical aspects of such approaches in animal research are discussed, and suggestions are given as to where to go from here.

APA, Harvard, Vancouver, ISO, and other styles

31

Barkley, Russell. "Child clinicians need for psychopharmacology training." Pharmacology Biochemistry and Behavior 36, no. 2 (June 1990): 430. http://dx.doi.org/10.1016/0091-3057(90)90461-p.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

M. Marlyne, Kilbey. "Survey of graduate training in psychopharmacology." Pharmacology Biochemistry and Behavior 36, no. 2 (June 1990): 430. http://dx.doi.org/10.1016/0091-3057(90)90462-q.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Shin, Cheolmin, Changsu Han, Chi-un Pae, and Ashwin A. Patkar. "Precision medicine for psychopharmacology: a general introduction." Expert Review of Neurotherapeutics 16, no. 7 (May 6, 2016): 831–39. http://dx.doi.org/10.1080/14737175.2016.1182022.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Solanto, M. V. "Clinical psychopharmacology of AD/HD: Implications for animal models." Neuroscience & Biobehavioral Reviews 24, no. 1 (January 2000): 27–30. http://dx.doi.org/10.1016/s0149-7634(99)00061-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Stoyanov, D. S. "AS09-02 - Translational cross-validation among neuroscience and psychiatry: prospects for diagnostic assessment and psychopharmacology." European Psychiatry 27 (January 2012): 1. http://dx.doi.org/10.1016/s0924-9338(12)73976-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Servitje, Lorenzo. "Of Drugs and Droogs: Cultural Dynamics, Psychopharmacology, and Neuroscience in Anthony Burgess’s A Clockwork Orange." Literature and Medicine 36, no. 1 (2018): 101–23. http://dx.doi.org/10.1353/lm.2018.0004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Goldberg, Joseph F., and A. John Rush. "Addressing the unmet needs of current antidepressants: does neuroscience help or hinder clinical psychopharmacology research?" Expert Opinion on Pharmacotherapy 18, no. 14 (August 11, 2017): 1417–20. http://dx.doi.org/10.1080/14656566.2017.1363178.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Hynie, S. "Serotonin in biological psychiatry, advances in biochemical psychopharmacology." Neuropharmacology 25, no. 1 (January 1986): 114–15. http://dx.doi.org/10.1016/0028-3908(86)90075-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Smillie, Luke D. "What is reinforcement sensitivity? Neuroscience paradigms for approach‐avoidance process theories of personality." European Journal of Personality 22, no. 5 (August 2008): 359–84. http://dx.doi.org/10.1002/per.674.

Full text

Abstract:

Reinforcement sensitivity is a concept proposed by Gray (1973) to describe the biological antecedents of personality, and has become the common mechanism among a family of personality theories concerning approach and avoidance processes. These theories suggest that 2–3 biobehavioural systems mediate the effects of reward and punishment on emotion and motivation, and that individual differences in the functioning of these systems manifest as personality. Identifying paradigms for operationalising reinforcement sensitivity is therefore critical for testing and developing these theories, and evaluating their footprint in personality space. In this paper I suggest that, while traditional self‐report paradigms in personality psychology may be less‐than‐ideal for this purpose, neuroscience paradigms may offer operations of reinforcement sensitivity at multiple levels of approach and avoidance processes. After brief reflection on the use of such methods in animal models—which first spawned the concept of reinforcement sensitivity—recent developments in four domains of neuroscience are reviewed. These are psychogenomics, psychopharmacology, neuroimaging and category‐learning. By exploring these paradigms as potential operations of reinforcement sensitivity we may enrich our understanding of the putative biobehavioural bases of personality. Copyright © 2008 John Wiley & Sons, Ltd.

APA, Harvard, Vancouver, ISO, and other styles

40

Stevens, Janice R. "Psychopharmacology of psychosis: Still looking for missing links." Behavioral and Brain Sciences 10, no. 2 (June 1987): 223–24. http://dx.doi.org/10.1017/s0140525x00047658.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Marais, Lelanie, Willie Daniels, Linda Brand, Francois Viljoen, Charmaine Hugo, and Dan J. Stein. "Psychopharmacology of maternal separation anxiety in vervet monkeys." Metabolic Brain Disease 21, no. 2-3 (July 19, 2006): 191–200. http://dx.doi.org/10.1007/s11011-006-9011-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Hynie, S. "Psychopharmacology of clonidine, progress in clinical and biological research." Neuropharmacology 25, no. 1 (January 1986): 116–17. http://dx.doi.org/10.1016/0028-3908(86)90078-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Hynie, S. "Molecular Pharmacology of Neurotransmitter Receptors, Advances in Biochemical Psychopharmacology." Neuropharmacology 25, no. 12 (December 1986): 1405. http://dx.doi.org/10.1016/0028-3908(86)90118-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Hicks, Robert E., James P. Mayo, and Claudia J. Clayton. "Differential Psychopharmacology of Methylphenidate and the Neuropsychology of Childhood Hyperactivity." International Journal of Neuroscience 45, no. 1-2 (January 1989): 7–32. http://dx.doi.org/10.3109/00207458908986213.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Grabb, Margaret C., and Jogarao V. S. Gobburu. "Challenges in developing drugs for pediatric CNS disorders: A focus on psychopharmacology." Progress in Neurobiology 152 (May 2017): 38–57. http://dx.doi.org/10.1016/j.pneurobio.2016.05.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Castellano, Claudio, Simona Cabib, and Stefano Puglisi-Allegra. "Psychopharmacology of memory modulation: Evidence for multiple interaction among neurotransmitters and hormones." Behavioural Brain Research 77, no. 1-2 (May 1996): 1–21. http://dx.doi.org/10.1016/0166-4328(96)00200-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Leonard, B. E. "Schizophrenia Research (Advances in Neuropsychiatry and Psychopharmacology, Vol. 1)." Neurochemistry International 19, no. 3 (January 1991): 384–85. http://dx.doi.org/10.1016/0197-0186(91)90026-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Geyer, Mark A. "MDMA and the psychopharmacology of presynaptic serotonin releasers." Pharmacology Biochemistry and Behavior 39, no. 1 (May 1991): 236. http://dx.doi.org/10.1016/0091-3057(91)90478-k.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Caixeta, Leonardo, and Victor Melo Caixeta. "Therapeutic synergism: How can psychopharmacology improve cognitive rehabilitation?" Dementia & Neuropsychologia 13, no. 4 (December 2019): 422–26. http://dx.doi.org/10.1590/1980-57642018dn13-040009.

Full text

Abstract:

ABSTRACT Despite recent advances in cognitive rehabilitation of patients with cognitive disorders, there are many major obstacles to the optimized global use of this therapeutic resource. Objective: The authors outline the concept of ‘therapeutic synergism’, i.e. the concurrent use of pharmacological and cognitive rehabilitation therapies to maximize functional benefits, addressing the optimization of therapeutic approaches for cognitive disorders. Methods: Three psychopharmacological and rehabilitation interrelationship paradigms are presented in three different clinical settings. Results: Paradigm 1: Behavioral and cognitive symptoms that hinder a cognitive rehabilitation program, but can be improved with psychopharmacology. Paradigm 2: Cognitive symptoms that hinder cognitive rehabilitation, but can be improved with anticholinesterases. Paradigm 3: Behavioral symptoms that hamper the use of cognitive rehabilitation, but can be improved by psychotropic drugs. Conclusion: Judicious use of psychotropic drugs in cognitive disorders can benefit, directly or indirectly, cognitive functions, thereby favoring other treatment modalities for cognitive impairment, such as neuropsychological rehabilitation.

APA, Harvard, Vancouver, ISO, and other styles

50

Benkert, O., and W. Maier. "The interface of clinical psychopharmacology and psychopathology." European Archives of Psychiatry and Neurological Sciences 238, no. 5-6 (July 1989): 280–84. http://dx.doi.org/10.1007/bf00449809.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!